Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regencell Bioscience Limited

18.50
+5.8846.59%
Pre-market: 28.009.50+51.35%04:04 EDT
Volume:3.36M
Turnover:58.83M
Market Cap:240.74M
PE:-55.96
High:19.80
Open:12.81
Low:12.71
Close:12.62
Loading ...
Oct 25, 2024

Annual Report

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
Oct 28, 2023

Annual Report

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
Oct 31, 2022

Annual Report

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
Jul 26, 2022

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
May 16, 2022

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Apr 04, 2022

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Dec 30, 2021

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Dec 15, 2021

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Jul 13, 2021

Correspondence

CORRESP [Cover] - Correspondence
Jul 13, 2021

Correspondence

CORRESP [Cover] - Correspondence
Jul 08, 2021

[Supp]Public Prospectus

FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
Jun 30, 2021

[Supp]Public Prospectus

FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
Jun 23, 2021

[Amend]Public Prospectus

F-1/A [Amend] - Registration statement for certain foreign private issuers
Jun 22, 2021

Correspondence

CORRESP [Cover] - Correspondence
Jun 11, 2021

[Amend]Public Prospectus

F-1/A [Amend] - Registration statement for certain foreign private issuers
Jun 11, 2021

Correspondence

CORRESP [Cover] - Correspondence